Polio: The Near-Eradication Story

One of history's most feared diseases is on the brink of eradication. Only two countries remain endemic.

99% Reduction in cases
2 Endemic Countries
350K Annual Paralysis (1988)

Disease Overview

What is Polio?

Poliomyelitis (polio) is a highly infectious disease caused by poliovirus (enterovirus). It primarily affects children under 5 years of age.

  • Types: Wild poliovirus types 1, 2, 3 (type 2 eradicated 1999)
  • Transmission: Fecal-oral route, highly contagious
  • Cases per infection: ~72% asymptomatic, ~24% mild, ~1% paralytic
  • Paralysis type: Spinal (most common), bulbar, bulbospinal

Clinical Presentation

  1. 1 Non-specific: fever, sore throat, headache
  2. 2 Aseptic meningitis (1-5% of cases)
  3. 3 Acute flaccid paralysis (0.1-1% of cases)
  4. 4 Post-polio syndrome (years later)

Pre-Vaccine Era: The Paralysis Epidemic

Polio was one of the most feared diseases of the 20th century. Unlike other childhood diseases that had existed for centuries, polio emerged as a major epidemic in the early 1900s, peaking in the 1950s.

350K

Annual cases of paralytic polio globally (1988)

15K-20K

Annual U.S. paralytic polio cases (1940s-1950s)

50K

U.S. polio deaths annually at peak

Why Polio Became an Epidemic

  • Improved sanitation paradoxically increased polio risk - fewer early exposures meant more susceptible older children
  • No natural immunity in the population as epidemics were a new phenomenon
  • Highly efficient spread in modern, mobile societies

Global Eradication Campaign

GPEI Timeline

1988 WHO, UNICEF, CDC, Rotary launch Global Polio Eradication Initiative (GPEI)
1994 Americas certified polio-free
2000 Western Pacific certified polio-free
2014 Southeast Asia certified polio-free
2020 Africa certified polio-free (wild virus)
2023 Only 2 endemic countries: Afghanistan, Pakistan

Vaccine Types

OPV (Oral Polio Vaccine)

Sabin vaccine - live attenuated. Provides gut immunity, excellent for outbreak response. Being phased out globally (bOPV).

IPV (Inactivated Polio Vaccine)

Salk vaccine - killed virus. Provides humoral immunity but not gut immunity. Now standard in most countries.

Eradication Achievements

  • 99.9% reduction in wild polio cases
  • Wild poliovirus type 2 declared eradicated (2015)
  • Wild poliovirus type 3 declared eradicated (2019)
  • 6 of 6 WHO regions certified

Current Situation & Challenges

Remaining Challenges

Despite near-eradication, polio remains a global health threat due to conflict zones, vaccine hesitancy, and vaccine-derived poliovirus outbreaks.

Endemic Countries (2024)

Afghanistan

6 wild poliovirus cases (2024)

Pakistan

9 wild poliovirus cases (2024)

Challenges: Conflict in border regions, vaccine misinformation, access limitations

Vaccine-Derived Poliovirus (VDPV)

  • cVDPV2 outbreaks (2023)30+ countries
  • VDPV cases (2023)500+
  • CauseCirculating OPV

Solution: Switch from tOPV to bOPV, increased IPV use, outbreak response with novel OPV2

Polio Vaccines: OPV vs IPV

Two vaccine types are used in the global eradication effort. The choice depends on the epidemiological context.

View Complete Vaccine Catalog →

IPV (Inactivated)

  • Type: Killed virus (Salk)
  • Administration: Injection
  • Immunity: Humoral (blood) only
  • Advantages: Safe, no VDPV risk
  • Disadvantage: No gut immunity

OPV (Oral)

  • Type: Live attenuated (Sabin)
  • Administration: Oral drops
  • Immunity: Gut + humoral
  • Advantages: Excellent for outbreaks
  • Disadvantage: Rare VDPV risk